The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 02, 2024
Filed:
Nov. 02, 2016
Applicant:
Takeda Pharmaceutical Company Limited, Osaka, JP;
Inventors:
Olga De La Rosa, Madrid, ES;
Eleuterio Lombardo, Madrid, ES;
Wilfried Dalemans, Leuven, BE;
Javier Garcia Casado, Caceres, ES;
Rebeca Blazquez Duran, Caceres, ES;
Francisco Miguel Sanchez Margallo, Caceres, ES;
Assignee:
TAKEDA PHARMACEUTICAL COMPANY LIMITED, Osaka, JP;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 35/02 (2015.01); A61K 9/127 (2006.01); A61K 9/50 (2006.01); C12N 15/62 (2006.01); A61P 29/00 (2006.01); A61P 37/06 (2006.01); A61K 45/06 (2006.01); A61K 35/35 (2015.01); A61K 31/519 (2006.01); A61K 31/4709 (2006.01); A61K 31/444 (2006.01); A61K 31/4439 (2006.01); A61K 31/5377 (2006.01); G01N 1/40 (2006.01); C12N 5/0775 (2010.01); A61K 35/12 (2015.01); A61K 35/28 (2015.01);
U.S. Cl.
CPC ...
A61K 35/28 (2013.01); A61K 9/127 (2013.01); A61K 9/5068 (2013.01); A61K 31/444 (2013.01); A61K 31/4439 (2013.01); A61K 31/4709 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 35/35 (2013.01); A61K 45/06 (2013.01); A61P 29/00 (2018.01); A61P 37/06 (2018.01); C12N 15/625 (2013.01); A61K 2035/122 (2013.01); A61K 2035/128 (2013.01); A61K 2300/00 (2013.01); C12N 5/0667 (2013.01); G01N 1/4077 (2013.01);
Abstract
The invention relates to exosomes derived from mesenchymal stem cells and well as isolated populations of said exosomes and method for preparing said isolated exosome populations. The invention also relates to a pharmaceutical composition comprising said exosome or isolated exosome population and their use in a method of treating an immune-mediated inflammatory disease in a subject.